1. Home
  2. PMAX vs JAGX Comparison

PMAX vs JAGX Comparison

Compare PMAX & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$2.79

Market Cap

4.5M

Sector

N/A

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$1.07

Market Cap

3.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
JAGX
Founded
2019
2013
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5M
3.9M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
PMAX
JAGX
Price
$2.79
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
1.7M
376.4K
Earning Date
09-23-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,799,100.00
$11,785,000.00
Revenue This Year
N/A
$22.41
Revenue Next Year
N/A
$30.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
12.45
52 Week Low
$1.56
$1.00
52 Week High
$22.00
$33.25

Technical Indicators

Market Signals
Indicator
PMAX
JAGX
Relative Strength Index (RSI) 56.80 39.04
Support Level $2.17 $1.06
Resistance Level $2.94 $1.30
Average True Range (ATR) 0.22 0.15
MACD 0.01 0.01
Stochastic Oscillator 60.00 2.22

Price Performance

Historical Comparison
PMAX
JAGX

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: